Metergoline and bromocriptine in the management of tumoral and idiopathic hyperprolactinemia

L. Falsetti, A. Roggia, G. Loda, R. Turla, T. Scagliola, M. Schimberni, A. E. Pontiroli

Research output: Contribution to journalArticlepeer-review


59 patients affected by amenorrhea or anovulation, 37 of whom also with galactorrhea, and with hyperprolactinemia of unknown origin (idiopathic hyperprolactinemia, 24 patients) or due to a pituitary microadenoma (tumoral hyperprolactinemia, 35 patients) were treated with metergoline (4-12 mg/day) or with bromocriptine (2.5 to 10 mg/day) for 90 days. The effectiveness of the two treatments was assessed on clinical grounds and by evaluating at montly intervals serum progesterone levels, during the presumed luteal phase, and serum prolactin levels. The success rate with the two drugs was superimposable in terms of disappearance of galactorrhea and return of menses, normalization of prolactin levels and induction of ovulation. Also the number of pregnancies obtained (7 with metergoline, 9 with bromocriptine) was similar. With both drugs, the majority of patients responded to the treatment within the first month.

Original languageEnglish
Pages (from-to)380-384
Number of pages5
JournalHormone and Metabolic Research
Issue number8
Publication statusPublished - 1983

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology


Dive into the research topics of 'Metergoline and bromocriptine in the management of tumoral and idiopathic hyperprolactinemia'. Together they form a unique fingerprint.

Cite this